At present, the blockade of PD-1/PD-L1 remains insufficient in the context of triple-negative breast cancer (TNBC), partially attributed to the existence of transforming growth factor-beta (TGF-β) as indicated by Yin et al. [52]. The gene discussed is TGFB1; the disease is triple-negative breast carcinoma.